Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012

Summary Slides

CIBMTR® CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH

Location of Centers Participating in the CIBMTR 2012

CIBMTR®

Transplant Activity in the U.S. 1980-2011



CIBMTR®

Allogeneic Stem Cell Sources by Recipient Age 2001-2010



CIBMTR®

Autologous Stem Cell Sources by Recipient Age, 2001-2010



CIBMTR®

Trends in Transplants by Type and Recipient Age* 2001-2010



CIBMTR®

* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma

Trends in Transplants by Transplant Type and Recipient Age* 1990-2010



CIBMTR®

* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma

Indications for Hematopoietic Stem Cell Transplants in the United States, 2010

(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)



CIBMTR®

Indications for Hematopoietic Stem Cell Transplants for Age ≤ 20yrs, in the U.S., 2010

(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)



CIBMTR®

Allogeneic Transplants for Age ≤ 20yrs, Registered with the CIBMTR, 1993-2010

- by Donor Type and Graft Source -



CIBMTR®

Allogeneic Transplants for Age > 20yrs, Registered with the CIBMTR, 1993-2010

- by Donor Type and Graft Source -



CIBMTR®

Unrelated Donor Stem Cell Sources by Recipient Age 2001-2010



CIBMTR®

Unrelated Cord Blood Transplants by Age Registered with the CIBMTR 2001-2010



CIBMTR®

One-year Survival by Year of Transplant, Donor and Age, Worldwide, 1997-2010

- In any remission, Acute Leukemia, CML or MDS-



CIBMTR®

100-day Mortality after Autologous Transplants, 2010



CIBMTR®

100-day Mortality after HLA-identical Sibling Transplants, 2010



CIBMTR®

100-day Mortality after Unrelated Donor Transplants, 2008-2009



CIBMTR®

Causes of Death after Transplants Done in 2009-2010

HLA-identical Sibling



Unrelated Donor



Autologous



CIBMTR®

Allogeneic Transplants Registered with the CIBMTR, 2001-2010

- by Conditioning Regimen Intensity & Age -



CIBMTR®

Allogeneic Transplants after Reduced-intensity Conditioning, by Donor Type, Registered with CIBMTR 1998-2010



CIBMTR®

Percentage of Reduced Intensity Conditioning Allo-HCTs, Registered with CIBMTR, 1998-2010

- by Year of Transplant & Disease -



CIBMTR®

Indications for Hematopoietic Stem Cell Transplants for Age ≥ 50yrs, in the U.S., 2010



CIBMTR®

Allogeneic Transplants in the U.S., Registered with the CIBMTR, 2007-2011

- by Donor Type -



CIBMTR®

Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipients by Group Age 2008-2011



CIBMTR®

Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010

- By Disease Status -



CIBMTR®

Survival after HLA-identical Sibling Donor Transplants for AML, Age <20 yrs, 2000-2010

- by Disease Status -



CIBMTR®

Probability of Survival after Autologous Transplants for AML, 2000-2010

- by Disease Status -



CIBMTR®

Probability of Survival after Allogeneic Transplants for MDS, 2000-2010

- by Disease Status and Donor Type -



CIBMTR®

Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 yrs, 2000-2010

- by Disease Status -



CIBMTR®

Probability of Survival after Unrelated Donor Transplants for ALL, Age < 20 yrs, 2000-2010

- By Disease Status -



CIBMTR

Survival after HLA-identical Sibling Donor Transplants for ALL, Age ≥ 20 yrs, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after Unrelated Donor Transplants for ALL, Age ≥ 20 yrs, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010

- By Disease Status and Transplant Year -



CIBMTR®

Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010

- by Donor Type and Conditioning Regimen Intensity -



CIBMTR®

Probability of Survival after Allogeneic Transplants for SAA, 2000-2010

- By Donor Type and Age -



CIBMTR®

Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010

- By Conditioning Regimen and Donor Type -



CIBMTR®

Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010

- By Disease Status -

CIBMTR®

Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010

- By Disease Status -



CIBMTR®

Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010

- By Donor Type -



CIBMTR®

Probability of Survival after Transplants for Multiple Myeloma, 2000-2010

- By Donor Type -



CIBMTR®